Real World Assessment of Citicoline in Stroke Patients: A Comprehensive Analysis of Clinical Efficacy and Safety Outcomes
Main Article Content
Abstract
Introduction: A stroke is a sudden focal neurological deficit resulting from a vascular lesion. Symptoms typically
last longer than 24 h if the patient survives. Citicoline, an abbreviation of cytidine-5’- diphosphocholine, is an
endogenous chemical compound. It can be bought as a tablet or an injection. Citicoline, also known as cytidine
diphosphate choline, is a crucial pyrimidine 5’-nucleotide that plays a significant role in the body’s biochemical
processes. It serves as an essential pre-cursor in the synthesis of lecithin, or phosphatidylcholine, which is
vital for maintaining cellular membrane integrity and fluidity. Moreover, research suggests that citicoline may
have neuroprotective properties, potentially aiding recovery in conditions such as stroke and cognitive decline.
Citicoline has comprehensive neuroprotective properties. Materials and Methods: The study was performed in
80 patients with stroke. Fifty patients received citicoline and the remaining 30 patients did not receive citicoline.
The changes in activities of daily living (ADL) and degree of disability were measured using the Barthel index
(BI) and Modified Rankin Scale (mRS), respectively. All statistical analyses were carried out using post hoc
analysis. Results and Discussion: Males were predominant in our study. The predominant age group for
developing ischemic stroke was found to be 51–65 years. The common symptoms associated with stroke were
found to be slurring of speech (18.2%), right hemiparesis (13.5%), giddiness (9.4%), and left hemiparesis (8.8%).
Hypertension and diabetes mellitus have been identified as the most common comorbidity associated with stroke.
Conclusion: On comparing the BI and mRS of the stroke patients, clinically there is a significant improvement in
ADL, cognitive functions, and functional ability of both the test and control group. On screening the patients for
safety measures, no adverse event has been reported.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Attribution-Noncommercial 4.0 International License [CC BY-NC 4.0], which requires that reusers give credit to the creator. It allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, for noncommercial purposes only.